Chronic stress promotes pancreatic ductal adenocarcinoma progression via complement C5a-recruited myeloid-derived suppressor cells Authors: Siyuan Yang, Li Xiao, Pingqian Qi, Ziqing Liu, Zhuomin Chen, Ruijia Wei, Ruishan He, Qiwen Yu, Zizhou Yan, Suyi Xiong, Mengmeng Wang, Yanjuan Deng, Jinping Hu, Lv Zhou, Zhen Feng, Huan Deng Published: 2025 ABSTRACT Chronic stress is an established risk factor for pancreatic ductal adenocarcinoma (PDAC). Although the autonomic nervous system (ANS), a key component of the tumor microenvironment (TME), has been closely associated with PDAC pathogenesis and prognosis, the underlying mechanisms remain incompletely understood. This study reveals that chronic stress-induced sympathetic nervous system (SNS) activation upregulates the hepatic complement system, leading to the recruitment of myeloid-derived suppressor cells (MDSCs) that promotes tumor progression. Specifically, chronic stress-triggered neurotransmitter norepinephrine (NE) enters the liver via systemic circulation and binds to upregulated β1 adrenergic receptor (ADRB1) on hepatocytes, enhancing the expression of complement components C3, C5, and CFH. In murine chronic stress-model, elevated systemic and intratumoral complement component 5a (C5a) levels correlated positively with MDSC expansion in both the spleen and tumor tissues. The effect was abrogated by the C5aR1 antagonist PMX-53, identifying C5a as a critical mediator of MDSC accumulation. MDSCs infiltrating the TME exhibited elevated expression of programmed death-ligand 1 (PD-L1) and transforming growth factor-β (TGF-β), contributing to an immunosuppressive niche. Intervention with the ADRB1 antagonist atenolol in PDAC mice significantly reduced serum/tumoral C5a levels, diminished splenic/intratumoral MDSCs proportions, and attenuated tumor growth. Our findings propose that targeting the SNS-driven complement-MDSCs axis represents a promising strategy for PDAC patients.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00262-025-04249-z. Introduction The complex interplay among components of the tumor microenvironment (TME), including parenchymal cells, nerves, and immune cells, is a critical determinant of the poor prognosis of pancreatic ductal adenocarcinoma (PDAC) patients [1, 2]. Chronic stress, a psychological state resulting from persistent and unresolved stressors, has been implicated in PDAC pathogenesis and progression through dysregulation of the autonomic nervous system (ANS) [3]. The ANS, comprising two major efferent branches (the sympathetic nervous system, SNS, and parasympathetic nervous system, PSNS), not only maintains systemic homeostasis but increasingly emerges as a key modulator of chronic diseases and tumor progression [4, 5]. In PDAC, SNS with aberrant density or hyperactivity releases high levels of catecholamines that promote PDAC cell survival by suppressing antitumor immune responses [6–9]. In contrast, PSNS exerts dual tumor-suppressive mechanisms via cholinergic signaling in pancreatic tumors. It directly downregulates MAPK and PI3K/AKT signaling cascades in cancer cells and may potentially mediate indirect antitumor effects through the inhibition of myeloid cell [10]. Paradoxically, SNS activation has also been reported to inhibit tumor growth via downregulation of CCL2 in macrophages [11]. This apparent contradiction underscores the complexity of SNS function, particularly its interactions with key TME components such as immune cells, stromal cells, and vascular endothelial cells, in shaping tumor behavior. Myeloid-derived suppressor cells (MDSCs), first described by Gabrilovich et al. [12], constitute a heterogeneous population of immunosuppressive cells involved in the pathological continuum from chronic inflammation to cancer metastasis [13]. In the setting of chronic inflammation, MDSCs expand and are recruited to lesion sites, where they contribute to the establishment of an immunosuppressive TME [14]. Growing evidence supports the hypothesis that chronic stress-induced sympathetic activation promotes MDSC mobilization via catecholamine release. In restraint stress models, MDSC expansion and accumulation have been observed in the bone marrow, peripheral blood, and spleen [15, 16]. Similar patterns were reported in tumor-bearing mice subjected to chronic restraint stress or chronic unpredictable mild stress (CUMS) [17–19]. Intriguingly, however, repetitive restraint stress was associated with a paradoxical reduction in splenic MDSCs [20]. These findings suggest that sustained stimulation may trigger systemic pathways that modulate both the expansion and spatial distribution of MDSCs. The liver serves as the primary site of complement production, with hepatocytes synthesizing approximately 90% of the core proteins [21]. The complement cascade, a critical element of the innate immunity, can be initiated through classical, alternative, and lectin pathways, which converge at a common terminal stage, leading to the formation of the membrane attack complex (MAC), which mediates target cell lysis and clearance [22]. Within this cascade, complement component C5 occupies a central position, bridging upstream activation steps to downstream effector functions [23, 24]. Anaphylatoxin C5a, a key bioactive molecule released upon activation of all complement pathways, participates in multiple facets of tumor biology, including immune evasion, progression, and metastasis [25]. C5a exerts context-dependent immunomodulatory effects that can promote tumor progression in a manner influenced by tumor type and local concentration [26]. However, the precise molecular mechanisms remain incompletely elucidated. MDSCs, as critical components of the immune microenvironment, exhibit a positive correlation between surface expression of C5a receptor 1 (C5aR1) and their capacity to infiltrate tumors [27]. Through this receptor/ligand axis, C5a recruits MDSCs to tumor sites, ultimately driving CD8⁺ T cell exhaustion and accelerating tumor progression [28]. Chronic stress exerts dual control over tumor development through the autonomic nervous system (ANS), directly influencing the malignant phenotypes and indirectly promoting tumorigenesis by remodeling the TME. A key mechanistic insight is that stress-induced sympathetic activation profoundly impacts MDSCs, which consistently express β-adrenergic receptors (β-ARs). As core orchestrators of immunosuppression, MDSCs employ a multifaceted strategy. They directly suppress effector T cell activity and promote the differentiation of regulatory T cells (Tregs) through the production of potent cytokines including IL-10 [29]. While chronic stress is known to facilitate PDAC progression through MDSCs, the molecular mechanisms governing MDSC expansion, systemic redistribution, and immunosuppressive TME modeling remain poorly characterized. Here we identify a previously unrecognized regulatory pathway mediated by SNS-induced C5a, which is mainly produced by the NE/ADRB1 axis-activated hepatocytes and promotes the expansion of MDSCs in the spleen and infiltration in PDAC, where it facilitates the establishment of immunosuppressive TME through programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-β1). Thus, SNS couples chronic stress to intrinsically primed immature immune cells, thereby accelerating the progression of PDAC. Materials and methods Animals and cell line Male C57BL/6J mice (6–8 weeks old) were used in this study. All mice were purchased from GemPharmatech Co., Ltd. (Nanjing, China) and housed in the Animal Facility of Nanchang University under specific pathogen-free (SPF) conditions. The animals were group-housed (3–5 per cage) with ad libitum access to food and water, and maintained in a temperature-controlled room (21–25°C) with 40–60% humidity under a 12-h light/dark cycle (lights on from 6:00 AM to 6:00 PM). The murine pancreatic cancer cell line Pan02 was obtained from Fuheng Biotechnology (Shanghai, China) and cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin–streptomycin (Gibco) at 37°C in a humidified incubator containing 5% CO2. All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of the Affiliated Rehabilitation Hospital, Jiangxi Medical College, Nanchang University (Approval No. SFYYXLL-PJ-2021-KY005). Orthotopic transplantation model Orthotopic PDAC model was established in male C57BL/6J mice by surgical implantation of 2 × 106 Pan02 cells into the pancreas as previously described [30]. Briefly, mice were anesthetized via intraperitoneal injection of Zoletil-50 and placed in a sterile surgical field. A small left abdominal incision was made to expose the pancreas, followed by orthotopic injection of 2 × 106 Pan02 cells suspended in 100 μL phosphate-buffered saline (PBS) into the head of the pancreas (PDAC mice). Successful intrapancreatic delivery was confirmed by the appearance of a transient tissue bulge. The needle was withdrawn slowly to minimize cell leakage, and the abdominal incision was sutured layer by layer. Establishment of CUMS model The CUMS protocol, a widely validated chronic stress paradigm [31], was initiated 3 days after tumor cell inoculation. PDAC mice were subjected to 2–3 randomly assigned stressors per day, including physical restraint, cage tilting (45°), tail suspension, water or food deprivation, circadian rhythm disruption, or exposure to white noise (CUMS/PDAC mice). Stressor type and sequence were randomized according to a non-repetitive schedule, with each specific stressor reappearing at intervals of no less than 7 days throughout the 14-day CUMS period. Open-field test (OFT) Behavioral analysis was performed in a 40 × 40 × 35 cm open-field arena. Each mouse from different groups was individually placed in the center of the arena and allowed to explore freely for 10 min while being recorded by the ANY-maze™ software (Stoelting Co.). The central zone was defined as the innermost 25% of total area. Total distance moved; dwell time and path length within the central zone were quantified. Elevated plus maze (EPM) test The EPM apparatus consisted of two open arms (28 × 5 cm) and two enclosed arms (28 × 5 × 15 cm) elevated 80 cm above the floor. Each mouse was placed in the central quadrant facing an open arm, and its exploratory behavior was video-tracked for 10 min. Metrics included total distance traveled, open arm residence time, and open arm path length. Pharmacological interventions Tumor-bearing mice were randomly assigned to treatment groups. Starting on day 3 post-tumor implantation, the following agents were administered daily via intraperitoneal injection: Atenolol (a selective β1-adrenergic receptor antagonist; 10 mg/kg/day; MedChemExpress, USA), PMX-53 (a C5aR1 antagonist; 10 mg/kg/day; MCE, USA), and SB-431542 (TGF-β receptor inhibitor; 30 mg/kg/day; MCE, USA). For PD-L1 blockade, an anti-PD-L1 antibody (10 mg/kg; MedChemExpress, USA) was injected intraperitoneally twice per week for 2 weeks. Hepatocyte isolation Mice were anesthetized with Zoletil-50 (Virbac), after which the portal vein was cannulated and perfused sequentially with Liver Perfusion Buffer and Liver Digest Medium (both from Thermo Fisher, USA). The distended liver was then excised, and hepatocytes were liberated by mechanical disruption of the Glisson’s capsule. The suspension was filtrated through a 70 μm nylon mesh, and hepatocytes were collected via low-speed centrifugation at 50× for 5 min. Quantitative real-time PCR (qRT-PCR) Total RNA was extracted using TRIzol™ and reverse-transcribed into cDNA using the RevertAid First Strand cDNA Synthesis Kit (both from Thermo Fisher, USA). Quantitative PCR was performed on a StepOnePlus™ Real-Time PCR system (Applied Biosystems, USA) using Hieff UNICON® SYBR Green Master Mix (Yeasen, China). Primer sequences used in this study are listed in Supplementary Table S1. Flow cytometric analysis Single-cell suspensions were prepared from the spleen or tumor tissues. The spleen was mechanically dissociated through a 70 μm filter, followed by red blood cell lysis with RBC Lysis Buffer (BioLegend, USA). Tumor tissues were digested with 1 mg/ml Collagenase IV (Beyotime, China). Murine MDSCs were defined as CD45+CD11b+Gr-1+ cells [5]. Cells were incubated with anti-CD16/32 (Clone 2.4G2; BD Biosciences, USA) to block Fc receptors, and then stained with CD45-BV421 (Clone 30-F11; BioLegend, USA), CD11b-FITC (Clone M1/70; BD Biosciences, USA), Ly-6G/Ly-6C-PE (Clone RB6-8C5; BD Biosciences, USA). Viability was assessed using 7-AAD (BD Biosciences, USA). Samples were acquired on a CytoFLEX LX flow cytometer (Beckman Coulter) and analyzed with FlowJo (v10.6.2). Cell sorting was performed using a CytoFLEX SRT system. Enzyme-linked immunosorbent assay (ELISA) For serum collection, blood was allowed to clot for 1 h and then centrifuged at 3000×g for 15 min. Tissue lysates were prepared by homogenizing samples in RIPA buffer (Beyotime, China) supplemented with a protease inhibitor cocktail. The concentrations of C5a (Novus Biologicals, NBP2-67681, USA) and NE (Elabscience, E-EL-0042c, China) were quantified according to manufacturers' protocols. Immunohistochemistry Tissues were fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned at a thickness of 5 μm. After deparaffinization, antigen retrieval was performed using citrate buffer (pH 6.0). Endogenous peroxidase were quenched. Sections were blocked with 5% goat serum and then incubated overnight with an anti-Ki-67 primary antibody (ZM-0166, ZSGB-BIO, China). DAB chromogen (Dako, Denmark) and hematoxylin counterstaining were applied. Ki-67+ cells were quantified using ImageJ software (analyzing at least three random fields per section). Transcriptome sequencing Sorted MDSCs from PDAC tissues were lysed in TRIzol® reagent for RNA extraction. RNA integrity (RIN > 8.0) was confirmed using Agilent 2100 Bioanalyzer. Sequencing libraries were constructed using the VAHTS Universal V6 RNA-seq Library Kit (Vazyme, China) and sequenced on a NovaSeq 6000 platform (Illumina, USA) to generate 150 bp paired-end reads. Raw sequencing reads were quality-controlled and adapter-trimmed using fastp (v0.23.2). Subsequent alignment of the processed reads was performed against the mouse reference genome (mm10). Statistical analysis Data are presented as the mean ± standard error of the mean (SEM). Differences between two groups were assessed using an unpaired, two-tailed Student’s t test. For comparisons across multiple groups, one-way ANOVA was applied, followed by Tukey’s post hoc test for multiple comparisons. All statistical analyses were performed using GraphPad Prism software (version 9.5). A p value of less than 0.05 was considered statistically significant. Results Chronic stress promotes PDAC progression To investigate the role of chronic stress in PDAC progression, we established a CUMS model in mice with orthotopic PDAC tumors. After a 3-day postoperative recovery period, mice were exposed to a intermittent stressor for 2 weeks prior to behavioral assessments and endpoint analyses (Fig. 1A). Anxiety-like behaviors were evaluated using the OFT and elevated plus maze (EPM).Fig. 1Chronic stress promotes PDAC growth. A Schematic diagram of PDAC cell line inoculation, CUMS exposure, and behavioral testing protocol. B Movement trajectories of control group (n = 11 per group) and CUMS group (n = 11 per group) mice in the open-field test. C CUMS intervention did not affect baseline locomotor activity in the open-field test (p = 0.2322). D–E CUMS significantly reduced the distance traveled (p = 0.0241) and time spent (p = 0.0040) in the central zone of the open field. F Movement trajectories of control group (n = 11 per group) and CUMS group (n = 11 per group) mice in the elevated plus maze. G CUMS intervention did not impair baseline locomotor activity in the elevated plus maze (p = 0.0867). H–I CUMS significantly decreased the exploration distance (p = 0.0469) and time (p = 0.0141) in the open arms of the elevated plus maze. J CUMS induced a reduction in body weight (n = 6 per group). K–L CUMS significantly increased tumor weight (n = 6 per group, p = 0.0064). M–N CUMS markedly elevated the Ki-67 positive rate in pancreatic tumor tissues (original magnification, × 400; n = 5 per group, p = 0.0496). n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001. n indicates biological replicates Chronic stress promotes PDAC growth. A Schematic diagram of PDAC cell line inoculation, CUMS exposure, and behavioral testing protocol. B Movement trajectories of control group (n = 11 per group) and CUMS group (n = 11 per group) mice in the open-field test. C CUMS intervention did not affect baseline locomotor activity in the open-field test (p = 0.2322). D–E CUMS significantly reduced the distance traveled (p = 0.0241) and time spent (p = 0.0040) in the central zone of the open field. F Movement trajectories of control group (n = 11 per group) and CUMS group (n = 11 per group) mice in the elevated plus maze. G CUMS intervention did not impair baseline locomotor activity in the elevated plus maze (p = 0.0867). H–I CUMS significantly decreased the exploration distance (p = 0.0469) and time (p = 0.0141) in the open arms of the elevated plus maze. J CUMS induced a reduction in body weight (n = 6 per group). K–L CUMS significantly increased tumor weight (n = 6 per group, p = 0.0064). M–N CUMS markedly elevated the Ki-67 positive rate in pancreatic tumor tissues (original magnification, × 400; n = 5 per group, p = 0.0496). n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001. n indicates biological replicates In the OFT, the total distance traveled showed a decreasing trend but did not differ significantly between PDAC and CUMS/PDAC mice, indicating that chronic stress did not markedly impair basal locomotor activity (Fig. 1B and C). Compared with PDAC controls, CUMS/PDAC mice exhibited a significant reduction in both path length (Fig. 1D) and dwell time (Fig. 1E) in the central zone. Although a similar decreasing trend was observed in the total travel distance, the difference was not statistically significant (Fig. 1F and G), confirming that chronic stress did not markedly impair basal locomotor function. Similarly, CUMS/PDAC mice exhibited significantly suppressed exploratory behavior in open arms and central quadrants, as demonstrated by decreased path length (Fig. 1H) and residence time (Fig. 1I). Collectively, these behavioral alterations confirm that CUMS successfully induced anxiety-like states in PDAC mice. Chronic stress is known to suppress appetite in rodents [32, 33]. Body weight measurements taken every 4 days revealed progressive weight loss in CUMS/PDAC mice relative to PDAC controls (Fig. 1J), further validating the effectiveness of the stress paradigm. Meanwhile, CUMS-exposed mice developed significantly heavier pancreatic tumors compared to controls (Fig. 1K and L). Immunohistochemical analysis further demonstrated elevated proliferation in the CUMS groups, evidenced by a pronounced increase in Ki-67+ cells (Fig. 1M and N). Collectively, these findings indicate that chronic stress exacerbates PDAC growth by enhancing tumor cell proliferation. Chronic stress drives MDSC expansion and infiltration To assess the effect of chronic stress on immune infiltration in pancreatic tumors, we quantified CD11b⁺Gr-1⁺ MDSCs in PDAC tissues by flow cytometry. After 20 days of CUMS, MDSC infiltration in pancreatic tumors was significantly higher in CUMS/PDAC mice than in controls (Fig. 2A and B), suggesting that chronic stress promotes MDSC accumulation in the TME.Fig. 2Chronic stress promotes MDSC expansion and infiltration. A–B FCM analysis revealed an increased proportion of CD11b⁺Gr-1⁺ MDSCs in PDAC tumor tissues under CUMS conditions (n = 5 per group, p = 0.0411). C–D CUMS elevated the percentage of CD11b⁺Gr-1⁺ MDSCs in the spleen (n = 5 per group, p = 0.0278). n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001. n indicates biological replicates Chronic stress promotes MDSC expansion and infiltration. A–B FCM analysis revealed an increased proportion of CD11b⁺Gr-1⁺ MDSCs in PDAC tumor tissues under CUMS conditions (n = 5 per group, p = 0.0411). C–D CUMS elevated the percentage of CD11b⁺Gr-1⁺ MDSCs in the spleen (n = 5 per group, p = 0.0278). n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001. n indicates biological replicates Given that such accumulation could arise from systemic expansion or local recruitment, we further assessed the proportion of MDSCs in the spleen, a systemic immune reservoir. Notably, CUMS treatment led to a significant increase in the proportion of splenic MDSCs (Fig. 2C and D). These results indicate that chronic stress concurrently drives both the systemic expansion and tumor-specific infiltration of MDSCs. Complement C5a mediates MDSC recruitment To gain further insight into the regulatory role of the complement system in the stress response, we harvested liver tissues from PDAC and CUMS/PDAC mice. qRT-PCR showed that while C2 expression remained unchanged (Fig. 3A), the transcript levels of the complement factors C3, C5, and CFH were significantly upregulated (Fig. 3B–D). This distinct expression profile indicates that chronic stress induces hepatic reprogramming, favoring the synthesis of specific complement components.Fig. 3Chronic stress promotes tumor MDSCs recruitment via complement C5a. A–D CUMS increased mRNA levels of C3 (p = 0.0230), C5 (p = 0.0295), and CFH (p = 0.0303) in hepatocytes, while C2 (p = 0.6717) mRNA levels remained unchanged (n = 4 per group). E–F CUMS elevated C5a levels in peripheral blood (p = 0.0004) and tumor tissues (p = 0.0243) (n = 4 per group). G–H Under chronic stress, the C5aR1 antagonist PMX-53 reduced the percentage of CD11b⁺Gr-1⁺ MDSCs in PDAC tumors (n = 5 per group, p = 0.0381). I–J PMX-53 decreased the percentage of CD11b⁺Gr-1⁺ MDSCs in the spleen under chronic stress (n = 5 per group, p = 0.0353). K–L Blockade of C5a signaling significantly reduced tumor weight (n = 6 per group, p = 0.0264). n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001. n indicates biological replicates Chronic stress promotes tumor MDSCs recruitment via complement C5a. A–D CUMS increased mRNA levels of C3 (p = 0.0230), C5 (p = 0.0295), and CFH (p = 0.0303) in hepatocytes, while C2 (p = 0.6717) mRNA levels remained unchanged (n = 4 per group). E–F CUMS elevated C5a levels in peripheral blood (p = 0.0004) and tumor tissues (p = 0.0243) (n = 4 per group). G–H Under chronic stress, the C5aR1 antagonist PMX-53 reduced the percentage of CD11b⁺Gr-1⁺ MDSCs in PDAC tumors (n = 5 per group, p = 0.0381). I–J PMX-53 decreased the percentage of CD11b⁺Gr-1⁺ MDSCs in the spleen under chronic stress (n = 5 per group, p = 0.0353). K–L Blockade of C5a signaling significantly reduced tumor weight (n = 6 per group, p = 0.0264). n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001. n indicates biological replicates We therefore focused on C5a, a cleavage product of C5 known to recruit MDSCs via C5aR1 [28]. Consistently, CUMS elevated C5a levels in both the serum and tumor tissues (Figs. 3E and F). To functionally establish the contribution of the C5a/C5aR1 axis to chronic stress-induced MDSC accumulation, we administered the C5aR1 antagonist PMX-53. This treatment effectively attenuated the CUMS-induced CD11b⁺Gr-1⁺ MDSCs accumulation in tumors (Fig. 3G and H) and spleens (Figs. 3I and J), confirming C5a/C5aR1 axis dependency. Importantly, C5aR1 blockade also suppressed PDAC growth (Fig. 3K and L), demonstrating that disrupting CD11b⁺Gr-1⁺ MDSCs recruitment can counteract chronic stress-accelerated tumor progression. SNS regulates C5a production via NE/ADRB1 signaling To investigate how SNS regulates complement production, we first measured the key neurotransmitter NE and found its serum concentration significantly elevated in CUMS/PDAC mice compared to PDAC controls (Fig. 4A). As NE exerts its effects via adrenergic receptors, including β (β1, β2, β3), α1(α1a, α1b, α1d), and α2 (α2a, α2b, α2c) subtypes [34], we profiled their hepatic expression. This screening revealed that CUMS selectively upregulated hepatic ADRB1 mRNA (Fig. 4B), without altering other ARs (Fig. 4C–J).Fig. 4Sympathetic nerves regulate C5a-mediated MDSCs recruitment via the NE/ADRB1 axis. A CUMS increased peripheral blood norepinephrine (NE) levels (n = 4 per group, p = 0.0124). B–G CUMS significantly upregulated mRNA levels of ADRB1 (one of the nine NE receptor subtypes) in hepatocytes (n = 3–4 per group, p = 0.0351). K Under chronic stress, the ADRB1 inhibitor atenolol markedly reduced hepatic C5 mRNA levels (n = 5 per group, p = 0.0251). L–M CUMS combined with atenolol attenuated C5a levels in peripheral blood (p < 0.001) and tumor tissues (p = 0.0226) of CUMS-exposed mice (n = 4 per group). N–Q Atenolol significantly decreased the percentage of CD11b⁺Gr-1⁺ MDSCs in PDAC tumors (n = 5 per group, p = 0.0014) and the spleen (n = 5 per group, p = 0.0014). R–S Chronic stress-induced tumor weight was significantly reduced by atenolol (n = 5 per group, p = 0.0026). n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001. n indicates biological replicates Sympathetic nerves regulate C5a-mediated MDSCs recruitment via the NE/ADRB1 axis. A CUMS increased peripheral blood norepinephrine (NE) levels (n = 4 per group, p = 0.0124). B–G CUMS significantly upregulated mRNA levels of ADRB1 (one of the nine NE receptor subtypes) in hepatocytes (n = 3–4 per group, p = 0.0351). K Under chronic stress, the ADRB1 inhibitor atenolol markedly reduced hepatic C5 mRNA levels (n = 5 per group, p = 0.0251). L–M CUMS combined with atenolol attenuated C5a levels in peripheral blood (p < 0.001) and tumor tissues (p = 0.0226) of CUMS-exposed mice (n = 4 per group). N–Q Atenolol significantly decreased the percentage of CD11b⁺Gr-1⁺ MDSCs in PDAC tumors (n = 5 per group, p = 0.0014) and the spleen (n = 5 per group, p = 0.0014). R–S Chronic stress-induced tumor weight was significantly reduced by atenolol (n = 5 per group, p = 0.0026). n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001. n indicates biological replicates To interrogate ADRB1’s role in stress-induced complement synthesis, we administered the ADRB1 antagonist atenolol (10 mg/kg/day). Atenolol attenuated CUMS-induced upregulation of hepatic C5 mRNA (Fig. 4K) and subsequently reduced serum and tumoral C5a levels (Fig. 4L and M). Mechanistically, chronic stress triggers SNS-derived NE to activate hepatic ADRB1, thereby stimulating C5 synthesis. Crucially, atenolol reversed CUMS-induced CD11b⁺Gr-1⁺ MDSC accumulation in tumors (Fig. 4N and O) and spleens (Fig. 4P and Q), concomitant with reduced tumor burden (Fig. 4R and S). Compared with PDAC controls, both PMX-53 and atenolol treatments significantly attenuated chronic stress-induced MDSC infiltration in the spleen obtained from CUMS/PDAC mice (p < 0.05). Critically, the two interventions were equally effective (p > 0.05), indicating that blocking upstream sympathetic signaling (via atenolol) or inhibiting the downstream complement cascade (via PMX-53) can similarly reverse MDSC accumulation. Together, these results establish the NE/ADRB1 axis as a critical hepatic gateway that mediates chronic stress-induced complement-MDSC crosstalk. Chronic stress potentiates MDSC immunosuppression Having established that chronic stress drives the expansion of CD11b⁺Gr-1⁺ MDSCs, we next investigated whether it also alters their functional reprogramming. Transcriptomic profiling of tumor-infiltrating MDSCs identified 560 differentially expressed genes in the CUMS group (260 upregulated, 300 downregulated; Fig. 5A–C). Gene Ontology (GO) analysis indicated enrichment in terms related to immune response regulation and complement receptor activity (Fig. 5D), while KEGG pathway analysis implicated the involvement of extracellular matrix interactions and PD-L1/PD-1 signaling pathway (Fig. 5E).Fig. 5Chronic stress enhances the immunosuppressive function of MDSCs in the tumor microenvironment. A Bar plot showing upregulated and downregulated differentially expressed genes (DEGs) between control and CUMS groups (n = 4 per group). B Volcano plot illustrating DEGs (upregulated and downregulated) between control and CUMS groups. C Heatmap displaying hierarchical clustering patterns of DEGs between groups. D Top 30 Gene Ontology (GO) enrichment terms of DEGs between control and CUMS groups. E Top 30 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis (bubble plot) of DEGs. F Enrichment analysis of CD274 (PD-L1) and TGF-β1 expression between control and CUMS groups. G–H CUMS significantly increased PD-L1 and TGF-β1 mRNA levels in tumor-infiltrating CD11b⁺Gr-1⁺ MDSCs (n = 4 per group, p < 0.001). I–J The TGF-β1 inhibitor SB-431542 and anti-PD-L1 antibody attenuated chronic stress-induced tumor growth (n = 6 per group, p < 0.001). n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001. n indicates biological replicates Chronic stress enhances the immunosuppressive function of MDSCs in the tumor microenvironment. A Bar plot showing upregulated and downregulated differentially expressed genes (DEGs) between control and CUMS groups (n = 4 per group). B Volcano plot illustrating DEGs (upregulated and downregulated) between control and CUMS groups. C Heatmap displaying hierarchical clustering patterns of DEGs between groups. D Top 30 Gene Ontology (GO) enrichment terms of DEGs between control and CUMS groups. E Top 30 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis (bubble plot) of DEGs. F Enrichment analysis of CD274 (PD-L1) and TGF-β1 expression between control and CUMS groups. G–H CUMS significantly increased PD-L1 and TGF-β1 mRNA levels in tumor-infiltrating CD11b⁺Gr-1⁺ MDSCs (n = 4 per group, p < 0.001). I–J The TGF-β1 inhibitor SB-431542 and anti-PD-L1 antibody attenuated chronic stress-induced tumor growth (n = 6 per group, p < 0.001). n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001. n indicates biological replicates A targeted screen of key immunosuppressive mediators from this dataset revealed upregulation of CD274 (which encodes PD-L1) and TGF-β1 (Fig. 5F). We validated this finding by qRT-PCR, confirming that CUMS-derived CD11b⁺Gr-1⁺ MDSCs indeed exhibited significantly elevated mRNA levels of PD-L1 and TGF-β1 (Fig. 5G and H). To assess the functional contribution of these pathways, we administered a TGF-β1 receptor inhibitor (SB-431542) and an anti-PD-L1 antibody (Fig. 5I). This combined blockade significantly attenuated tumor growth (Fig. 5J). Thus, these findings mechanistically connect chronic stress to the functional potentiation of MDSCs, which occurs through the synergistic upregulation of PD-L1 and TGF-β1. Discussion The landscape of neuroimmunology research in PDAC has dramatically evolved over the past decade. Here, we elucidate a novel sympathetic/complement axis that mediates chronic stress-accelerated PDAC progression. SNS-derived NE activates hepatic ADRB1 signaling, upregulating the complement component C5a in both the circulation and the PDAC TME. Concurrently, chronic stress elevates systemic NE levels and splenic MDSC proportions. The elevated C5a, in turn, promotes the expansion and tumor infiltration of CD11b⁺Gr-1⁺ MDSCs, a process previously implicated in C5a-mediated chemotaxis [28]. Mechanistically, we further reveal that chronic stress functionally reprograms infiltrating MDSCs to adopt a potent immunosuppressive phenotype characterized by two complementary actions: (1) direct suppression of CD8+ T cell cytotoxicity through PD-L1 overexpression, and (2) TME remodeling through TGF-β1 secretion. These two mechanisms operate synergistically to enhance tumor immune evasion and fuel PDAC progression (Fig. 6).Fig. 6Chronic stress promotes PDAC progression via NE/C5a axis-mediated recruitment of MDSCs Chronic stress promotes PDAC progression via NE/C5a axis-mediated recruitment of MDSCs Previous studies have demonstrated that chronic stress can directly promote PDAC progression through SNS-mediated release of NE [9]. Concurrent clinical observations have noted substantial infiltration of immature myeloid-derived immune cells adjacent to tumor parenchymal cells. MDSCs, as pivotal immunosuppressive players in the TME, are strongly correlated with poor prognosis in PDAC [35]. These cells accelerate cancer progression and undermine the efficacy of immunotherapies through diverse molecular mechanisms, including the establishment of immunosuppressive niches, promotion of tumor angiogenesis, facilitation of dissemination and metastasis, and induction of therapy resistance [36]. Although MDSCs express high levels of β-adrenergic receptors, the precise molecular mechanisms by which SNS regulates MDSCs dynamics remain poorly understood. In this study, we demonstrated that CUMS significantly increased MDSC infiltration in both the spleen and pancreatic TME, indicating that SNS activation drives systemic MDSC expansion and subsequent recruitment to malignancies. This finding supports the notion that SNS indirectly fuels PDAC progression by reshaping the immunosuppressive properties of the TME. Morphologically, murine MDSCs (CD11b+Gr-1+) are categorized into two main subtypes: polymorphonuclear-like (PMN-MDSCs) and monocytic-like MDSCs (M-MDSCs) [37, 38]. While our work delineates the overarching impact of psychological stress on the accumulation of total MDSCs in the TME, future studies are warranted to dissect the subset-specific dynamics, relative contributions, and distinct mechanisms of PMN-MDSCs versus M-MDSCs. Such detailed investigation will be essential for a holistic interpretation of chronic stress-driven immunosuppressive remodeling in PDAC. Paradoxically, some studies report that the number and behavior of MDSCs in stress models do not significantly differ from those in untreated littermates [15, 17]. This discrepancy maybe context-dependent, as catecholamine-driven MDSC mobilization and immunosuppressive potentiation appear to occur predominantly in the setting of established tumors or chronic inflammation [39]. These observations imply the existence of alternative pathways in SNS-mediated MDSC regulation. Although complement activation has been proposed as a modulator of MDSC dynamics [40], the specific physiological triggers that engage this pathway remain elusive. Chronic stress represents a physiological stimulus that pathologically activates SNS, leading to systemic NE overproduction and subsequent physiological perturbations [41, 42]. Our findings align with this paradigm by demonstrating a temporally synchronized triad of events: elevated serum NE, upregulated hepatic ADRB1 expression, and increased C5a concentrations in both circulation and tumors. Critically, pharmacological inhibition of the NE/ADRB1 axis via atenolol disrupted these correlations and markedly suppressed hepatic complement production. This provides direct evidence linking chronic stress-induced sympathetic hyperactivity to the hepatic synthesis of complement proteins. This study establishes the complement system, particularly the terminal pathway component C5a, as a central mediator of tumor progression. Upon binding to its receptor C5aR1, C5a orchestrates a multifaceted program: It recruits and activates immunosuppressive cells such as MDSCs to dampen antitumor immunity and shape a permissive microenvironment; directly stimulates endothelial cell proliferation to fuel angiogenesis; and upregulates matrix metalloproteinases to enhance tumor cell invasiveness and metastatic potential [40, 43, 44]. Previous studies have shown that C5a recruits MDSCs into TME, where they impair cytotoxic T cell function through the release of reactive nitrogen and oxygen species, thereby fueling tumor proliferation [28, 45]. Consistent with these findings, our data demonstrate a positive correlation between serum and intratumoral C5a levels and the extent of CD11b⁺Gr-1⁺ MDSC infiltration. Pharmacological blockade of C5aR1 with PMX-53 significantly attenuated MDSC recruitment and suppressed tumor growth [46–48]. Based on these findings, we propose that MDSC infiltration is driven by a synergistic interplay between systemic and local regulation. Plasma C5a is primarily responsible for promoting the proliferation and differentiation of myeloid precursors, whereas locally activated complement within the tumor mainly creates a specialized niche for the recruitment of MDSCs [25]. Although broader immune cell interactions warrant further investigation, these data establish the C5a/C5aR1 axis as a pivotal pathway through which chronic stress reprograms the immunological landscape of PDAC TME. While SNS modulates systemic distribution and local infiltration of MDSCs via neurotransmitter-receptor interactions, its direct impact on MDSC biology has remained less clear. Having established that chronic stress recruits MDSCs into PDAC through SNS-driven complement activation, we investigated whether stress also reprograms their immunosuppressive activity within TME. High-throughput comparative transcriptomic profiling revealed that MDSCs isolated from CUMS tumors significantly upregulated key mediators PD-L1 and TGF-β1. The PD-1/PD-L1 axis, a central regulator of immune homeostasis, enables tumor immune evasion by suppressing T cell activation [49]. MDSC-derived PD-L1 directly engages PD-1 on T cells, inducing anergy and apoptosis [50, 51]. Meanwhile, TGF-β1 further reinforces an immunosuppressive TME by promoting metastatic progression, stromal remodeling, and epithelial–mesenchymal transition [52, 53]. Therapeutic blockade of PD-L1 or TGF-β1 signaling significantly impeded tumor growth, suggesting that dual inhibition of these pathways could restore antitumor immunity and achieve durable clinical responses under chronic stress [54, 55]. Our work thus identifies a previously underappreciated role for SNS: directly potentiating immunosuppressive function of MDSCs to reshape the TME. Future studies should validate this paradigm in human PDAC specimens to guide diagnostic and therapeutic innovations. In summary, this study uncovers a novel neuroimmune axis whereby chronic stress remodels the immunosuppressive microenvironment in PDAC. Mechanistically, stress-induced sympathetic overactivation elevates circulating NE, which binds to upregulated β1-adrenergic receptors on hepatocytes, triggering complement activation. The ensuing rise in C5a, both systemically and within PDAC, drives a marked expansion of MDSCs in the spleen and their recruitment to TME, thereby accelerating tumor progression. A key finding is that blockade of either upstream sympathetic signaling (with atenolol) or downstream C5a/C5aR1 signaling (with PMX-53) similarly reduced MDSC infiltration, indicating that the complement component C5a serves as an essential effector downstream of sympathetic nervous system in a linear signaling cascade. Furthermore, chronic stress functionally reprograms MDSCs to overexpress PD-L1 and TGF-β1, thereby amplifying immune suppression and promoting tumor cell survival. These results systematically delineate the pathway from psychosocial stress to PDAC progression via neuroimmune crosstalk. Therapeutic targeting of this NE/C5a-recruited MDSCs may thus represent a promising strategy for improving PDAC treatment. Supplementary Information Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 14 kb) Supplementary file1 (DOCX 14 kb)